Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Parkinson's Disease

  Free Subscription


03.05.2021

1 Ann Neurol
2 Exp Brain Res
1 J Neural Transm (Vienna)
2 Lancet Neurol
12 Mov Disord
1 Neurobiol Dis
2 Neurochem Res
2 Neurology
1 Neurology (ECronicon)
1 Neuropsychology
2 Neurosci Lett
1 PLoS One
1 Rev Neurol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Neurol

  1. BLAUWENDRAAT C, Iwaki H, Makarious MB, Bandres-Ciga S, et al
    Investigation of Autosomal Genetic Sex Differences in Parkinson's disease.
    Ann Neurol. 2021 Apr 26. doi: 10.1002/ana.26090.
    PubMed         Abstract available


    Exp Brain Res

  2. MORRISON S, Moxey J, Reilly N, Russell DM, et al
    The relation between falls risk and movement variability in Parkinson's disease.
    Exp Brain Res. 2021 Apr 29. pii: 10.1007/s00221-021-06113.
    PubMed         Abstract available

  3. KOCOGLU K, Akdal G, Donmez Colakoglu B, Cakmur R, et al
    The effect of directional social cues on saccadic eye movements in Parkinson's disease.
    Exp Brain Res. 2021 Apr 29. pii: 10.1007/s00221-021-06034.
    PubMed         Abstract available


    J Neural Transm (Vienna)

  4. DE GROOTE E, Bockstael A, Botteldooren D, Santens P, et al
    Evaluation of multi-feature auditory deviance detection in Parkinson's disease: a mismatch negativity study.
    J Neural Transm (Vienna). 2021 Apr 24. pii: 10.1007/s00702-021-02341.
    PubMed         Abstract available


    Lancet Neurol

  5. TOLOSA E, Garrido A, Scholz SW, Poewe W, et al
    Challenges in the diagnosis of Parkinson's disease.
    Lancet Neurol. 2021;20:385-397.
    PubMed         Abstract available

  6. RIZIG M, Okubadejo N, Salama M, Thomas O, et al
    The International Parkinson Disease Genomics Consortium Africa.
    Lancet Neurol. 2021;20:335.
    PubMed        


    Mov Disord

  7. HANSS Z, Larsen SB, Antony P, Mencke P, et al
    Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient-Derived Neurons.
    Mov Disord. 2021;36:704-715.
    PubMed         Abstract available

  8. HO GPH, Ramalingam N, Imberdis T, Wilkie EC, et al
    Upregulation of Cellular Palmitoylation Mitigates alpha-Synuclein Accumulation and Neurotoxicity.
    Mov Disord. 2021;36:348-359.
    PubMed         Abstract available

  9. KIEBURTZ K, Katz R, McGarry A, Olanow CW, et al
    A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic.
    Mov Disord. 2021;36:59-63.
    PubMed         Abstract available

  10. VIEIRA-YANO B, Martini DN, Horak FB, de Lima-Pardini A, et al
    The Adapted Resistance Training with Instability Randomized Controlled Trial for Gait Automaticity.
    Mov Disord. 2021;36:152-163.
    PubMed         Abstract available

  11. SARANZA G, Lang AE
    Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia.
    Mov Disord. 2021;36:265-266.
    PubMed        

  12. POLISSIDIS A, Koronaiou M, Kollia V, Koronaiou E, et al
    Psychosis-Like Behavior and Hyperdopaminergic Dysregulation in Human alpha-Synuclein BAC Transgenic Rats.
    Mov Disord. 2021;36:716-728.
    PubMed         Abstract available

  13. YOUNCE JR, Campbell MC, Hershey T, Tanenbaum AB, et al
    Resting-State Functional Connectivity Predicts STN DBS Clinical Response.
    Mov Disord. 2021;36:662-671.
    PubMed         Abstract available

  14. SARTER M, Avila C, Kucinski A, Donovan E, et al
    Make a Left Turn: Cortico-Striatal Circuitry Mediating the Attentional Control of Complex Movements.
    Mov Disord. 2021;36:535-546.
    PubMed         Abstract available

  15. YILMAZ R, Suenkel U, Postuma RB, Heinzel S, et al
    Comparing the Two Prodromal Parkinson's Disease Research Criteria-Lessons for Future Studies.
    Mov Disord. 2021 Apr 30. doi: 10.1002/mds.28637.
    PubMed        

  16. SARANZA G, Villanueva EQ 3rd, Lang AE
    Preferences for Communication About End-of-Life Care in Atypical Parkinsonism.
    Mov Disord. 2021 Apr 28. doi: 10.1002/mds.28633.
    PubMed         Abstract available

  17. HUYNH B, Fu Y, Kirik D, Shine JM, et al
    Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease.
    Mov Disord. 2021 Apr 26. doi: 10.1002/mds.28615.
    PubMed         Abstract available

  18. TSUNEMI T, Oyama G, Saiki S, Hatano T, et al
    Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.
    Mov Disord. 2021 Apr 25. doi: 10.1002/mds.28595.
    PubMed         Abstract available


    Neurobiol Dis

  19. YIN Z, Zhu G, Zhao B, Bai Y, et al
    Local field potentials in Parkinson's disease: a frequency-based review.
    Neurobiol Dis. 2021 Apr 28:105372. doi: 10.1016/j.nbd.2021.105372.
    PubMed         Abstract available


    Neurochem Res

  20. WANG X, Liu Z, Wang F
    MicroRNA-93 Blocks Signal Transducers and Activator of Transcription 3 to Reduce Neuronal Damage in Parkinson's Disease.
    Neurochem Res. 2021 Apr 26. pii: 10.1007/s11064-021-03333.
    PubMed         Abstract available

  21. RATHORE AS, Birla H, Singh SS, Zahra W, et al
    Epigenetic Modulation in Parkinson's Disease and Potential Treatment Therapies.
    Neurochem Res. 2021 Apr 26. pii: 10.1007/s11064-021-03334.
    PubMed         Abstract available


    Neurology

  22. DONG Y, Cheng X, Dong Q
    Teaching NeuroImages: Parkinsonism Presenting With Watershed Pattern Lesions.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012056.
    PubMed        

  23. RIOU A, Houvenaghel JF, Dondaine T, Drapier S, et al
    Functional Role of the Cerebellum in Parkinson Disease: A PET Study.
    Neurology. 2021 Apr 28. pii: WNL.0000000000012036.
    PubMed         Abstract available


    Neurology (ECronicon)

  24. MANCINI JD, Yao S, Martinez LR, Shakil H, et al
    Gut Microbiome Changes with Osteopathic Treatment of Constipation in Parkinson's Disease: A Pilot Study.
    Neurology (ECronicon). 2021;13:19-33.
    PubMed         Abstract available


    Neuropsychology

  25. STOHLMAN SL, Barrett MJ, Sperling SA
    Factor structure of the BDI-II in Parkinson's disease.
    Neuropsychology. 2021 Apr 29. pii: 2021-40360-001. doi: 10.1037/neu0000739.
    PubMed         Abstract available


    Neurosci Lett

  26. VENKATESAN D, Iyer M, S RW, G L, et al
    The association between multiple risk factors, clinical correlations and molecular insights in Parkinson's disease patients from Tamil Nadu population, India.
    Neurosci Lett. 2021;755:135903.
    PubMed         Abstract available

  27. ZHANG L, Yang H
    Promotive effects of tetrahydroxystilbene glucoside on the differentiation of neural stem cells from the mesencephalon into dopaminergic neurons.
    Neurosci Lett. 2021;742:135520.
    PubMed         Abstract available


    PLoS One

  28. JENSEN BR, Malling ASB, Schmidt SI, Meyer M, et al
    Long-term treatment with transcranial pulsed electromagnetic fields improves movement speed and elevates cerebrospinal erythropoietin in Parkinson's disease.
    PLoS One. 2021;16:e0248800.
    PubMed         Abstract available


    Rev Neurol

  29. ALONSO-CANOVAS A, Martinez-Castrillo JC
    [Apomorphine: a powerful ally in Parkinson's disease].
    Rev Neurol. 2021;72:323-332.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: